Aurora Introduces Innovative Cannabis Oil Range to Meet Diverse Patient Needs in Australia
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), in partnership with MedReleaf Australia, has launched an enhanced range of premium medical cannabis oils in Australia. The new products include various cannabinoid ratios to meet diverse patient needs, such as Aurora THC 25 (Sativa and Indica), Aurora 12.5:12.5, Aurora 50:50, and Aurora 10:100 oils, all in 30mL bottles.
These oils are developed and manufactured at Aurora's Canadian TGA and EU GMP certified facility, offering healthcare providers and patients a broader selection of treatment options. The expanded product portfolio demonstrates Aurora's commitment to advancing patient care through high-quality, science-driven cannabis solutions.
Key features of the new cannabis oil products include comprehensive cannabinoid profiles, high standards of quality and safety, and a broad selection for customized patient care. Healthcare professionals can contact MedReleaf Australia's clinical support team for additional information.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), in collaborazione con MedReleaf Australia, ha lanciato una gamma ampliata di oli di cannabis medica premium in Australia. I nuovi prodotti includono diverse proporzioni di cannabinoidi per soddisfare le esigenze variabili dei pazienti, come gli oli Aurora THC 25 (Sativa e Indica), Aurora 12.5:12.5, Aurora 50:50 e Aurora 10:100, tutti in flaconi da 30 mL.
Questi oli sono sviluppati e prodotti presso l'impianto certificato TGA e EU GMP di Aurora in Canada, offrendo a fornitori di assistenza sanitaria e pazienti una selezione più ampia di opzioni terapeutiche. Il portafoglio di prodotti ampliato dimostra l'impegno di Aurora nell'avanzare la cura del paziente attraverso soluzioni di cannabis di alta qualità e basate sulla scienza.
Le caratteristiche chiave dei nuovi prodotti di olio di cannabis includono profili cannabinoidi completi, elevati standard di qualità e sicurezza, e una vasta selezione per una cura personalizzata del paziente. I professionisti della salute possono contattare il team di supporto clinico di MedReleaf Australia per ulteriori informazioni.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), en colaboración con MedReleaf Australia, ha lanzado una gama mejorada de aceites de cannabis medicinal premium en Australia. Los nuevos productos incluyen varias proporciones de cannabinoides para satisfacer las diversas necesidades de los pacientes, como los aceites Aurora THC 25 (Sativa e Indica), Aurora 12.5:12.5, Aurora 50:50 y Aurora 10:100, todos en botellas de 30 mL.
Estos aceites son desarrollados y fabricados en las instalaciones certificadas TGA y EU GMP de Aurora en Canadá, ofreciendo a proveedores de atención médica y pacientes una selección más amplia de opciones de tratamiento. El portafolio de productos ampliado demuestra el compromiso de Aurora con el avance de la atención al paciente a través de soluciones de cannabis de alta calidad y basadas en la ciencia.
Las características clave de los nuevos productos de aceite de cannabis incluyen perfiles cannabinoides completos, altos estándares de calidad y seguridad, y una amplia selección para la atención personalizada del paciente. Los profesionales de la salud pueden contactar al equipo de soporte clínico de MedReleaf Australia para obtener más información.
아우로라 캐너비스 주식회사 (NASDAQ: ACB) (TSX: ACB)는 메드릴리프 호주와 협력하여 호주에서 프리미엄 의료용 대마유의 향상된 제품군을 출시했습니다. 새로운 제품에는 환자의 다양한 요구를 충족하기 위해 여러 가지 칸나비노이드 비율이 포함되어 있으며, 아우로라 THC 25(사티바 및 인디카), 아우로라 12.5:12.5, 아우로라 50:50 및 아우로라 10:100 오일이 모두 30mL 병에 담겨 있습니다.
이 오일은 아우로라의 캐나다 TGA와 EU GMP 인증 시설에서 개발 및 제조됩니다, 의료 제공자와 환자에게 더 넓은 치료 옵션을 제공합니다. 확대된 제품 포트폴리오는 고품질의 과학 기반 대마 솔루션을 통해 환자 치료를 발전시키려는 아우로라의 의지를 보여줍니다.
새로운 대마유 제품의 주요 특징에는 포괄적인 칸나비노이드 프로필, 높은 품질 및 안전 기준, 맞춤형 환자 치료를 위한 광범위한 선택이 포함됩니다. 의료 전문가는 추가 정보를 위해 메드릴리프 호주 임상 지원 팀에 연락할 수 있습니다.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), en partenariat avec MedReleaf Australia, a lancé une gamme améliorée d'huiles de cannabis médicinal premium en Australie. Les nouveaux produits incluent différents rapports de cannabinoïdes pour répondre aux divers besoins des patients, tels que les huiles Aurora THC 25 (Sativa et Indica), Aurora 12.5:12.5, Aurora 50:50 et Aurora 10:100, toutes dans des bouteilles de 30 mL.
Ces huiles sont développées et fabriquées dans l'installation certifiée TGA et GMP de l'UE d'Aurora au Canada, offrant aux prestataires de soins de santé et aux patients une sélection plus large d'options de traitement. Le portefeuille de produits élargi démontre l'engagement d'Aurora à faire progresser les soins aux patients grâce à des solutions de cannabis de haute qualité et fondées sur la science.
Les caractéristiques clés des nouveaux produits d'huile de cannabis comprennent des profils de cannabinoïdes complets, des normes élevées de qualité et de sécurité, et une large sélection pour des soins personnalisés des patients. Les professionnels de santé peuvent contacter l'équipe de soutien clinique de MedReleaf Australia pour plus d'informations.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) hat in Zusammenarbeit mit MedReleaf Australia eine erweiterte Reihe von Premium-Medizin-Cannabisölen in Australien eingeführt. Die neuen Produkte umfassen verschiedene Cannabinoidverhältnisse, um den unterschiedlichen Bedürfnissen der Patienten gerecht zu werden, wie Aurora THC 25 (Sativa und Indica), Aurora 12.5:12.5, Aurora 50:50 und Aurora 10:100 Öle, alle in 30mL Flaschen.
Diese Öle werden in Auroras kanadischer TGA- und EU-GMP-zertifizierter Anlage entwickelt und hergestellt, was den Gesundheitsdienstleistern und Patienten eine breitere Auswahl an Behandlungsmöglichkeiten bietet. Das erweiterte Produktportfolio zeigt Auroras Engagement für die Verbesserung der Patientenversorgung durch qualitativ hochwertige, wissenschaftlich fundierte Cannabislösungen.
Die Hauptmerkmale der neuen Cannabisölprodukte umfassen umfassende Cannabinoidprofile, hohe Standards für Qualität und Sicherheit sowie eine breite Auswahl für eine individualisierte Patientenversorgung. Gesundheitsfachkräfte können das klinische Unterstützungsteam von MedReleaf Australia für weitere Informationen kontaktieren.
- Launch of new premium medical cannabis oil range in Australia
- Expanded product portfolio with various cannabinoid ratios
- Manufactured in TGA and EU GMP certified facilities
- Increased options for personalized patient treatment
- None.
Insights
The launch of Aurora's new cannabis oil range in Australia represents a significant expansion of treatment options for medical cannabis patients. This move demonstrates Aurora's commitment to the Australian market and its ability to leverage its global production capabilities to meet local demand.
The introduction of five new oil formulations with varying THC:CBD ratios is particularly noteworthy. This diversity allows for more precise dosing and personalized treatment plans, potentially improving patient outcomes. The inclusion of both Sativa and Indica THC oils also caters to different symptom management needs.
From a market perspective, this product expansion could strengthen Aurora's position in Australia's growing medical cannabis sector. The emphasis on TGA and EU GMP certification for manufacturing aligns with Australia's strict regulatory standards, which could facilitate easier market acceptance and potentially pave the way for future exports.
While this news is positive for Aurora's growth strategy, its immediate financial impact may be given Australia's relatively small market size compared to Aurora's global operations. However, it positions the company well for long-term growth in the Asia-Pacific region.
NASDAQ | TSX: ACB
Products for Enhanced Patient Care Options
The newly launched cannabis oil products include Aurora THC 25 (Sativa) in a 30mL bottle, Aurora THC 25 (Indica) in a 30mL bottle, Aurora 12.5:12.5 oil in a 30mL bottle, Aurora 50:50 oil in a 30mL bottle, and Aurora 10:100 oil in a 30mL bottle. Each formulation offers varying cannabinoid ratios to support personalized treatment options for patients.
"We are thrilled to bring this enhanced range of cannabis oil products to the Australian market," said Andre Jerome, Executive Vice President, Global Business Development at Aurora. "Our mission is to offer healthcare providers and their patients a broader selection of treatment options that meet their various medical needs. By expanding our product portfolio, we continue to demonstrate our commitment to advancing patient care through high-quality, science-driven cannabis solutions."
The newly available oils are developed and manufactured at Aurora's Canadian TGA and EU GMP certified facility, add to the expanding lineup with increased cannabinoid variety. The new products allow Doctors to tailor treatments more precisely, enhancing patient care. These offerings are another step forward in MedReleaf Australia's mission to expand access to quality medical cannabis options for patients across the country.
Key features of Aurora's new cannabis oil products include:
- Comprehensive Cannabinoid Profiles: Designed to provide targeted and effective relief with a variety of THC and CBD ratios.
- High Standards of Quality and Safety: Manufactured in TGA-GMP certified facilities, adhering to rigorous quality control measures.
- Broad Selection: Wide range of unique oil formulations, allowing for customized patient care.
For additional information, healthcare professionals are encouraged to contact MedReleaf Australia's clinical support team or visit their website: www.medreleafaustralia.com.au.
About Aurora Cannabis
Aurora is opening the world to cannabis, serving both the medical and consumer markets across
Aurora's Common Shares trade on the NASDAQ and TSX under the symbol "ACB".
About MedReleaf Australia
MedReleaf Australia is a subsidiary of Aurora Cannabis Inc., established in 2016. MedReleaf is licensed by the Australian Federal Government's Office of Drug Control (ODC) to cultivate and manufacture medical cannabis. MedReleaf also has licenses to import, export and wholesale medical cannabis. Its wholly owned subsidiary in
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the expansion of the Company's product portfolio in the Australian market and associated benefits, and the Company's continued commitment to advancing patient care and expanding access to medical cannabis globally.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-introduces-innovative-cannabis-oil-range-to-meet-diverse-patient-needs-in-australia-302277181.html
SOURCE Aurora Cannabis Inc.
FAQ
What new cannabis oil products has Aurora Cannabis (ACB) introduced in Australia?
Where are Aurora's (ACB) new cannabis oil products manufactured?
What are the key features of Aurora's (ACB) new cannabis oil products in Australia?
Who is Aurora Cannabis (ACB) partnering with to launch these new products in Australia?
